**Abstract:** 4CPS-217

SERVICIO DE SALUD DEL PRINCIPADO DE ASTURIAS
GERENCIA ÁREA SANITARIA IV
HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

# EFFECTIVENESS AND SAFETY OF ORAL VISCOUS BUDESONIDE IN COMPOUND FORMULATION: REAL WORLD DATA

M.MUÑOZ VILLASUR, C. RODRÍGUEZ-TENREIRO RODRÍGUEZ, I. MARAY MATEOS, I. DE LA FUENTE VILLAVERDE, S. FERNÁNDEZ LASTRAS, M. EIROA OSORO, L. OYAGUE LÓPEZ, C. FADÓN HERRERA, C. DÍAZ ROMERO, A. LOZANO BLÁZQUEZ.
HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS, HOSPITAL PHARMACY, OVIEDO, SPAIN

## Background and Importance

Budesonide is an anti-inflammatory corticosteroid whose viscous formulation enhances adherence to the esophageal mucosa, improving its local action in EoE.

## Aim and Objectives

To evaluate the effectiveness and safety of OVB in a compounded 0.5 mg/ml formulation for patients with EoE at a 1000-bed hospital.

## Materials and methods

Descriptive and retrospective study (March 2018-March 2024).
Patients diagnosed with EoE treated with OVB at least one 6-week induction phase.

- **Effectiveness** (6 weeks):
  - **Histological response**: <15 eosinophils/mm² (high-power field).
  - **Clinical response**: Symptom-free.
- **Safety**: Evaluated through adverse drug reactions and treatment discontinuation.

**Variables:**
Sex, age, prior treatments and response, OVB therapy duration and dosage, eosinophil count, clinical symptoms at 6 weeks, adverse reactions, and treatment discontinuation.

## Results

**62 patients** (77% male).
Median age: 33 (4–74).
Median age at diagnosis: 27 (4–65)

Median duration: 6 months (2–37).

Dose 1 mg/12h (53%)







## Conclusion and relevance

**OVB proved to be an effective treatment option for patients with EoE who are refractory to other therapies, showing high rates of histological and clinical response. It demonstrated an acceptable safety profile, with manageable and well-tolerated adverse events.**
**Further studies are needed to confirm these findings due to the limited sample size and short follow-up period.**

CONTACT DATA:
marinamuvi@outlook.com